Inactive Instrument

Company Tengion, Inc. Other OTC

Equities

TNGNQ

US88034G2084

Biotechnology & Medical Research

Business Summary

Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 40,245,124 40,245,124 ( 100.00 %) 0 100.00 %

Company contact information

Tengion, Inc.

3929 Westpoint Boulevard Suite G

27103, Winston-Salem

+

http://www.tengion.com
address Tengion, Inc.(TNGNQ)
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW